科拓生物
(300858)
| 流通市值：34.28亿 | | | 总市值：46.61亿 |
| 流通股本：1.94亿 | | | 总股本：2.63亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 267,389,193.46 | 163,345,625.11 | 77,612,862.67 | 302,793,277.36 |
| 营业收入 | 267,389,193.46 | 163,345,625.11 | 77,612,862.67 | 302,793,277.36 |
| 二、营业总成本 | 187,404,480.84 | 119,905,813.02 | 56,526,026.1 | 211,440,159.85 |
| 营业成本 | 128,245,917.3 | 82,916,596.7 | 38,548,876.48 | 126,410,969.06 |
| 税金及附加 | 3,132,902.91 | 2,320,854.35 | 612,186.92 | 5,274,382.5 |
| 销售费用 | 25,080,702.88 | 13,832,941.7 | 7,268,846.55 | 36,507,476.96 |
| 管理费用 | 21,278,385.14 | 14,050,358.7 | 7,195,697.6 | 31,395,566.37 |
| 研发费用 | 24,545,249.12 | 16,738,749.21 | 7,884,151.19 | 36,327,014.28 |
| 财务费用 | -14,878,676.51 | -9,953,687.64 | -4,983,732.64 | -24,475,249.32 |
| 其中:利息费用 | 144,027.51 | 140,603.95 | 139,586.82 | 251,040.48 |
| 其中:利息收入 | 14,528,534.93 | 10,108,533.51 | 5,130,122.38 | 24,757,594.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,436,693.57 | 956,219.16 | 316,957.27 | 2,013,454.04 |
| 加:投资收益 | 1,419,474.28 | 1,298,927.79 | 982,169.09 | 3,577,981.47 |
| 资产处置收益 | - | - | - | 652,262.64 |
| 信用减值损失(新) | -1,559,518.71 | -377,431.9 | 157,529.93 | 3,193,285.57 |
| 其他收益 | 7,229,049.97 | 4,554,818.53 | 2,789,709.85 | 8,672,581.21 |
| 四、营业利润 | 88,510,411.73 | 49,872,345.67 | 25,333,202.71 | 109,462,682.44 |
| 加:营业外收入 | 23,012.86 | 23,012.44 | 23,011.47 | 58,229.03 |
| 减:营业外支出 | 37,868.54 | 13,697.65 | 0 | 692,974.62 |
| 五、利润总额 | 88,495,556.05 | 49,881,660.46 | 25,356,214.18 | 108,827,936.85 |
| 减:所得税费用 | 12,263,558.32 | 8,676,597.42 | 5,026,589.55 | 14,471,856.39 |
| 六、净利润 | 76,231,997.73 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 76,231,997.73 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 76,231,997.73 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 |
| 扣除非经常损益后的净利润 | 67,077,516.38 | 35,126,939.95 | 16,664,806.63 | 82,282,318.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.29 | 0.16 | 0.08 | 0.36 |
| (二)稀释每股收益 | 0.29 | 0.16 | 0.08 | 0.36 |
| 八、其他综合收益 | -52.57 | 9.89 | -0.85 | 31.32 |
| 归属于母公司股东的其他综合收益 | -52.57 | 9.89 | -0.85 | 31.32 |
| 九、综合收益总额 | 76,231,945.16 | 41,205,072.93 | 20,329,623.78 | 94,356,111.78 |
| 归属于母公司股东的综合收益总额 | 76,231,945.16 | 41,205,072.93 | 20,329,623.78 | 94,356,111.78 |
| 公告日期 | 2025-10-22 | 2025-08-20 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |